ストックスクリーナーアプリを入手
0.5168
0.67%
-0.0035
Citius Pharmaceuticals Inc (CTXR) 最新ニュース
CTXR|Citius Pharmaceuticals Inc|Price:0.531|Chg%:+0.010 - TradingKey
Citius Pharmaceuticals Inc (CTXR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Citius Pharmaceuticals Inc (CTXR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Citius Pharmaceuticals Inc (CTXR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
CTXR|Citius Pharmaceuticals Inc|Price:0.520|Chg%:-0.011 - TradingKey
Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Citius Oncology Inc (CTOR) Institutional Confidence - TradingKey
Citius Pharmaceuticals (CTXR) Sidoti Micro-Cap Virtual Conference Summary - Quartr
Citius Oncology expands sales team for LYMPHIR launch By Investing.com - Investing.com Nigeria
Citius Oncology expands sales team for LYMPHIR launch - Investing.com
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption - Morningstar
Citius Oncology (Nasdaq: CTOR) sets $18M stock deal at $1.09 to back LYMPHIR launch - Stock Titan
Citius Oncology (CTOR) Registration filing Summary - Quartr
Enterprise value to revenue forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
Citius Pharmaceuticals (CTXR) Edges Lower, Testing Key Support at $0.51IV Crush Alert - dars.gov.et
Enterprise value to revenue forward of Citius Pharmaceuticals Inc – LS:A40MD0 - TradingView
CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Pharmaceuticals updates pipeline as investors track CTXR stock - Ad-hoc-news.de
Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is A Biotech Runner: Here's Why - Insider Financial
Citius Pharmaceuticals Q4 2025 Earnings: EPS Miss Exceeds 45% as Pre-Revenue Biotech Navigates Clinical MilestonesAdjusted Earnings Analysis - DonanımHaber
A40MD0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
Price to earnings forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Enterprise value to EBIT forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
47N0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Enterprise value to EBITDA forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
Citius Pharmaceuticals Inc Actuals & Estimates (FWB:47N0) - TradingView
Enterprise value to revenue forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Enterprise value to EBITDA forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Enterprise value to EBIT forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Citius Pharmaceuticals Inc Actuals & Estimates (NASDAQ:CTXR) - TradingView
CTXR Forecast — Price Target — Prediction for 2027 - TradingView
Citius Pharmaceuticals updates I/ ONTAK launch progress, shares trade on Nasdaq - AD HOC NEWS
Citius Pharmaceuticals Inc (CTXR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Citius Pharmaceuticals (CTXR) price target increased by 20.00% to 6.12 - MSN
Citius Pharmaceuticals Inc (CTXR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Citius Pharmaceuticals Inc (CTXR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Citius Pharmaceuticals Inc (CTXR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Citius Pharmaceuticals Inc (CTXR) Institutional Confidence - TradingKey
Citius Pharmaceuticals Inc (CTXR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
[EFFECT] CITIUS ONCOLOGY, INC. SEC Filing - Stock Titan
Citius Oncology (CTOR) stake updated by majority holder Citius Pharma - Stock Titan
[EFFECT] Citius Pharmaceuticals, Inc. SEC Filing - Stock Titan
Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers - TipRanks
Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data - Stock Titan
Citius Oncology (NASDAQ: CTXR) shares early Phase 1 LYMPHIR cancer data - Stock Titan
Citius Oncology (NASDAQ: CTOR) highlights Phase 1 LYMPHIR plus pembrolizumab results - Stock Titan
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies - BioSpace
Citius Oncology presents study data on LYMPHIR combination By Investing.com - Investing.com Australia
Citius Oncology presents study data on LYMPHIR combination - Investing.com
LYMPHIR combo study finds 24% response, disease control up to 35 months - Stock Titan
CTXR Q4 2025 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineMid-Term Outlook - DonanımHaber
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):